A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia

NCT02205099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SKL15508
DRUG: Placebo

Sponsor

SK Life Science, Inc.